Macrolyn is an antibiotic belonging to the macrolyde class
Active substance: azithromycin
Form: film-coated tablet
Dosage: Each tablet 500 mg azithromycin
Packaging: Box with 1 blister of 3 tablets
Target: Adults and children (<45 kg)
Macrolyn tablets are indicated for the treatment of the following infections, when caused by microorganisms sensitive to azithromycin:
Always take it exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The dosage for treatment of sexually transmitted diseases due to Chlamydia trachomatis, Haemophilus ducreyi or susceptible Neisseria gonorrhoeae is 1000 mg as a single oral dose.
The dosage for treatment of tonsillitis/pharyngitis due to S.pyogenes, is 500 mg on day 1 and 250 mg daily on days 2 through 5, the duration of therapy is 5 days.
For all other indications, total dosage is 1500 mg, taken as 500 mg daily for 3 days.
Children and adolescents under 45 kg should use other forms of this medicine.
Macrolyn® should be given as a single daily dose. The tablets should be taken with ½ glass of water. Macrolyn® can be taken 1 hour before or 2 hours after meals.
Always continue with the course even if you feel better. If your infection gets worse or you do not start to feel better within a few days or a new infection develops, go back and see your doctor.
Prescription drugs. Please contact your doctor.
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.
Dafra Pharma
